Gilead Sciences (GILD) has reported mixed news recently. While the biotech giant's shares have shown strength, seeing a rise of 1.14% and 0.52% on 22nd and 21st March respectively, it has also suffered a higher drop than the average market. Their attractiveness as an investment has been ratified by numerous billionaires and investment brokers, with many considering GILD undervalued. On the other hand, the company has had to weather several adverse events, including a potentially calamitous call from the HHS and the prospect of serious funding cuts to federal HIV programmes. Insider sell-offs by key individuals like Andrew Dickinson may also be cause for concern. However, GILD's recent financial results showed positive outcomes with the announcement of their Q4 earnings and overall financial results for 2024 displaying robust growth in areas like HIV and Oncology. Forecasts for 2025 remain positive, leading to a surge in the company's shares and even an upgrade from Deutsche Bank. There are also hints of promising advances in their HIV treatments, specifically with drugs like Lenacapavir and Biktarvy.
Gilead Sciences GILD News Analytics from Wed, 18 Sep 2024 07:13:33 GMT to Sat, 22 Mar 2025 05:25:02 GMT -
Rating 5
- Innovation 6
- Information 8
- Rumor 2
